{"id":"W2794958179","doi":"10.1053/j.gastro.2018.03.032","title":"Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease","year":2018,"lang":"en","type":"review","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"UCB Pharma; Toray Industries; Kyowa Hakko Kirin; Meso Scale Diagnostics; Ferring Research Institute; Novo Nordisk; Teva Pharmaceutical Industries; Janssen Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Arrien Pharmaceuticals; Celgene; Shire; Heron Therapeutics; Eli Lilly and Company; AstraZeneca; Western University; Takeda Pharmaceutical Company; Roche","keywords":"Medicine; Clinical trial; Crohn's disease; Delphi method; Disease; Inflammatory bowel disease; Clinical endpoint; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001467048,0.0009260962,0.002427536,0.001590726,0.0001936224,0.0012313,0.001144702,0.001129507,0.002447328],"category_scores_gemma":[0.001767327,0.0002543627,0.0008338153,0.001099665,0.0005416395,0.001076013,0.0006391269,0.002253315,0.0009075869],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005595032,"about_ca_system_score_gemma":0.001246054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005472155,"about_ca_topic_score_gemma":0.001122774,"domain_scores_codex":[0.9996156,0.00008610512,0.00007987586,0.00005307393,0.0001309613,0.0000343865],"domain_scores_gemma":[0.9991208,0.0004498361,0.0001586005,0.00002486405,0.0002020002,0.00004387655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003638554,0.0001092406,0.0004988657,0.01644706,0.0002325978,0.0002536196,0.00003482582,0.0004152259,0.002487785,0.004103495,0.01406983,0.9609835],"study_design_scores_gemma":[0.0002600572,0.0005197069,0.002455424,0.009199535,0.0009175716,0.001586385,0.00009157887,0.0002903562,0.002504022,0.005912435,0.9762123,0.00005075178],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002422504,0.9980668,0.0003331067,0.0003581996,0.0001978558,0.00001072246,0.00004288503,0.000009901254,0.0007382863],"genre_scores_gemma":[0.002569086,0.9952161,0.0008400359,0.0004761102,0.00023272,0.00002368631,0.00009981996,0.00000344333,0.0005389571],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002447328,"threshold_uncertainty_score":0.008187175,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02560819691949784,"score_gpt":0.3108939057775107,"score_spread":0.2852857088580129,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}